Effectiveness and waning of protection with the BNT162b2 vaccine against the SARS-CoV-2 Delta variant in immunocompromised individuals

被引:4
作者
Szekanecz, Zoltan [1 ]
Voko, Zoltan [2 ,3 ]
Surjan, Orsolya [4 ]
Rakoczi, Eva [1 ]
Szamosi, Szilvia [1 ]
Szucs, Gabriella [1 ]
Szekanecz, Eva [5 ]
Mueller, Cecilia [6 ]
Kiss, Zoltan [7 ]
机构
[1] Univ Debrecen, Fac Med, Dept Rheumatol, Debrecen, Hungary
[2] Semmelweis Univ, Ctr Hlth Technol Assessment, Budapest, Hungary
[3] Syreon Res Inst, Budapest, Hungary
[4] Natl Publ Hlth Ctr, Dept Deputy Chief Med Officer 2, Budapest, Hungary
[5] Univ Debrecen, Fac Med, Dept Oncol, Debrecen, Hungary
[6] Natl Publ Hlth Ctr, Dept Chief Med Officer, Budapest, Hungary
[7] Univ Pecs, Med Sch, Diabet Ctr, Dept Med & Nephrol 2, Pecs, Hungary
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
SARS-CoV-2; COVID-19; immunocompromised patients; BNT162b2; vaccine; booster; vaccine effectiveness;
D O I
10.3389/fimmu.2023.1247129
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
IntroductionIn Hungary, the HUN-VE 3 study determined the comparative effectiveness of various primary and booster vaccination strategies during the Delta COVID-19 wave. That study included more than 8 million 18-100-year-old individuals from the beginning of the pandemic. Immunocompromised (IC) individuals have increased risk for COVID-19 and disease course might be more severe in them. In this study, we wished to estimate the risk of SARS-CoV-2 infection and COVID-19 related death in IC individuals compared to healthy ones and the effectiveness of the BNT162b2 vaccine by reassessing HUN-VE 3 data.Patients and methodsAmong the 8,087,988 individuals undergoing follow-up from the onset of the pandemic in the HUN-VE 3 cohort, we selected all the 263,116 patients with a diagnosis corresponding with IC and 6,128,518 controls from the second wave, before vaccinations started. The IC state was defined as two occurrences of corresponding ICD-10 codes in outpatient or inpatient claims data since 1 January, 2013. The control group included patients without chronic diseases. The data about vaccination, SARS-CoV-2 infection and COVID-19 related death were obtained from the National Public Health Center (NPHC) during the Delta wave. Cases of SARS-CoV-2 infection were reported on a daily basis using a centralized system via the National Public Health Center (NPHC).ResultsOut of the 263,116 IC patients 12,055 patients (4.58%) and out of the 6,128,518 healthy controls 202,163 (3.30%) acquired SARS-CoV-2 infection. Altogether 436 IC patients and 2141 healthy controls died in relation to COVID-19. The crude incidence rate ratio (IRR) of SARS-CoV-2 infection was 1.40 (95%CI: 1.37-1.42) comparing IC patients to healthy controls. The crude mortality rate ratio was 4.75 (95%CI: 4.28-5.27). With respect to SARS-CoV-2 infection, interestingly, the BNT162b2 vaccine was more effective in IC patients compared to controls. Primary vaccine effectiveness (VE) was higher in IC patients compared to controls and the booster restored VE after waning. VE regarding COVID-19 related death was less in IC patients compared to healthy individuals. Booster vaccination increased VE against COVID-19-related death in both IC patients and healthy controls.ConclusionThere is increased risk of SARS-CoV-2 infection and COVID-19 related mortality in IC patient. Moreover, booster vaccination using BNT162b2 might restore impaired VE in these individuals.
引用
收藏
页数:8
相关论文
共 39 条
  • [1] Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis
    Akiyama, Shintaro
    Hamdeh, Shadi
    Micic, Dejan
    Sakuraba, Atsushi
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (03) : 384 - 391
  • [2] Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative
    Andersen, Kathleen M.
    Bates, Benjamin A.
    Rashidi, Emaan S.
    Olex, Amy L.
    Mannon, Roslyn B.
    Patel, Rena C.
    Singh, Jasvinder
    Sun, Jing
    Auwaerter, Paul G.
    Ng, Derek K.
    Segal, Jodi B.
    Garibaldi, Brian T.
    Mehta, Hemalkumar B.
    Alexander, G. Caleb
    [J]. LANCET RHEUMATOLOGY, 2022, 4 (01) : E33 - E41
  • [3] [Anonymous], 2021, Updated joint statement from ECDC and EMA on additional booster doses of COVID-19 vaccines
  • [4] Adverse COVID-19 outcomes in immune deficiencies: Inequality exists between subclasses
    Aydiner, Elif Karakoc
    Eltan, Sevgi Bilgic
    Babayeva, Royale
    Aydiner, Omer
    Kepenekli, Eda
    Kolukisa, Burcu
    Sefer, Asena Pinar
    Gungoren, Ezgi Yalcin
    Karabiber, Esra
    Yucel, Esra Ozek
    Ozdemir, Oner
    Kiykim, Ayca
    Artac, Hasibe
    Yakici, Nalan
    Yalcin, Koray
    Cokugras, Haluk
    Celkan, Tulin Tiraje
    Orhan, Fazil
    Yesilipek, Mehmet Akif
    Baris, Safa
    Ozen, Ahmet
    [J]. ALLERGY, 2022, 77 (01) : 282 - 295
  • [5] EULAR 2021 updated viewpoints on SARS-CoV-2 vaccination in patients with RMDs: a guidance to answer patients' questions
    Bijlsma, Johannes W. J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (06) : 786 - 788
  • [6] Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial
    Bonelli, Michael
    Mrak, Daniel
    Tobudic, Selma
    Sieghart, Daniela
    Koblischke, Maximilian
    Mandl, Peter
    Kornek, Barbara
    Simader, Elisabeth
    Radner, Helga
    Perkmann, Thomas
    Haslacher, Helmuth
    Mayer, Margareta
    Hofer, Philipp
    Redlich, Kurt
    Husar-Memmer, Emma
    Fritsch-Stork, Ruth
    Thalhammer, Renate
    Stiasny, Karin
    Winkler, Stefan
    Smolen, Josef S.
    Aberle, Judith H.
    Zeitlinger, Markus
    Heinz, Leonhard X.
    Aletaha, Daniel
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (05) : 687 - 694
  • [7] Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series
    Caillard, Sophie
    Thaunat, Olivier
    Benotmane, Ilies
    Masset, Christophe
    Blancho, Gilles
    [J]. ANNALS OF INTERNAL MEDICINE, 2022, 175 (03) : 455 - +
  • [8] Migration and outbreaks of vaccine-preventable disease in Europe: a systematic review
    Deal, Anna
    Halliday, Rae
    Crawshaw, Alison F.
    Hayward, Sally E.
    Burnard, Amelia
    Rustage, Kieran
    Carter, Jessica
    Mehrotra, Anushka
    Knights, Felicity
    Campos-Matos, Ines
    Majeed, Azeem
    Friedland, Jon S.
    Edelstein, Michael
    Mounier-Jack, Sandra
    Hargreaves, Sally
    [J]. LANCET INFECTIOUS DISEASES, 2021, 21 (12) : E387 - E398
  • [9] Deepak P, 2021, medRxiv, DOI [10.1101/2021.04.05.21254656, 10.1101/2021.04.05.21254656, DOI 10.1101/2021.04.05.21254656]
  • [10] COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies
    Di Fusco, Manuela
    Lin, Jay
    Vaghela, Shailja
    Lingohr-Smith, Melissa
    Nguyen, Jennifer L.
    Sforzolini, Thomas Scassellati
    Judy, Jennifer
    Cane, Alejandro
    Moran, Mary M.
    [J]. EXPERT REVIEW OF VACCINES, 2022, 21 (04) : 435 - 451